Scholars Central

Research articlePublished 2016

Efficacy and Safety of Bivalirudin versus Heparin Plus Tirofiban in Elderly Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Authors: Ke Zhu, Wen Lu, Yi-jie Huang, Lin-guang Wang, Qiang Wu, Chun-guang Feng, Qiang Fu

Cardiovascular Pharmacology: Open Access

Volume 5 · Issue 1 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: The aim of this study was to investigate the antithrombotic effect and safety of Bivalirudin compared with heparin plus Tirofiban in elderly patients with acute myocardial infarction undergoing primary Percutaneous Coronary Intervention (PCI). Methods: One hundred and twenty elderly patients were randomly assigned to receive two different antithrombotic therapies (Group A: Bivalirudin alone or Group B: Heparin plus Tirofiban) in a 1:1 ratio according to the treatment sequence and a table of random numbers. The clinical information, routine examination results, infarct-related sites of the enrolled patients were recorded, and the Thrombolysis in Myocardial Infarction (TIMI) flow grade and other safety indexes after PCI were analyzed. Results: No statistically significant differences existed in ST-segment depression at 2 h after the intervention, post- PCI TIMI flow grade and reduction of N-terminal pro-B type natriuretic peptide (NT-proBNP) serum concentrations in patients on day 7 versus day 1 after PCI between the two groups (P>0.05). However, the adverse clinical events of bleeding showed significant differences in the two groups (P<0.05). Conclusion: Bivalirudin exerts confirmed anticoagulant effect and indicates a lower risk of bleeding compared with heparin plus Tirofiban in elderly patients with acute myocardial infarction undergoing primary PCI.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCardiovascular Pharmacology: Open Access
  • SubjectPharmaceutical Sciences
  • SubjectCardiology
  • BylineArticles whose byline prints “Ke Zhu”
  • BylineArticles whose byline prints “Wen Lu”
  • BylineArticles whose byline prints “Yi-jie Huang”
  • BylineArticles whose byline prints “Lin-guang Wang”
  • BylineArticles whose byline prints “Qiang Wu”
  • BylineArticles whose byline prints “Chun-guang Feng”
  • BylineArticles whose byline prints “Qiang Fu”